宫颈癌患者从诊断到治疗等待时间对预后影响的全国性人群研究
该全国性人群队列研究纳入2010至2019年新诊断宫颈癌并接受根治性手术或(放)化疗的患者,分析从病理确诊到治疗的等待时间与总生存的关系。结果显示,手术等待时间与总生存无显著关联(连续HR 0.97,95%CI 0.93-1.01),(放)化疗等待时间亦无显著关联(连续HR 0.97,95%CI 0.93-1.00)。结论认为,最长至12周的等待时间未对生存产生负面影响。
要点
- 手术等待时间与总生存无显著关联(连续HR 0.97,95%CI 0.93-1.01)。
- (放)化疗等待时间与总生存无显著关联(连续HR 0.97,95%CI 0.93-1.00)。
- 最长至12周的诊断至治疗等待时间未对生存产生负面影响。
核心结论
- 这项大型人群研究显示,宫颈癌患者接受根治性手术或(放)化疗时,从诊断到治疗等待时间最长至12周不会对生存产生负面影响。
研究设计与样本
- 全国性人群队列研究,纳入2010至2019年新诊断宫颈癌患者6895例,其中接受初始手术2755例、接受初始(放)化疗1898例。
主要发现
- 手术等待时间平均8.5(±4.2)周,连续变量HR 0.97(95%CI 0.93-1.01),二分类HR 0.93(95%CI 0.68-1.27),多项式模型HR不显著。
- (放)化疗等待时间平均7.7(±2.9)周,连续变量HR 0.97(95%CI 0.93-1.00),二分类HR 0.91(95%CI 0.75-1.09),多项式模型HR不显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior research underlined the importance of timely oncological care as longer waiting times from diagnosis to treatment may result in poorer survival outcomes. The aim of this study was to determine the impact of waiting time from diagnosis to treatment on overall survival (OS) in patients with cervical cancer treated with curative intent. METHODS: Patients from a nationwide population-based cohort with newly diagnosed cervical cancer between 2010 and 2019 were studied. Patients who underwent surgery or (chemo)radiotherapy with curative intent were selected. Waiting time (i.e. interval between first pathologic confirmation and treatment) was modelled as continuous (i.e. linear per week), dichotomized (i.e. ≤8 versus >8 weeks), and polynomial (i.e. restricted cubic splines). The association with OS was examined using Cox regression analyses. RESULTS: Among 6895 patients with cervical cancer, 2755 treated with primary surgery and 1898 who received primary (chemo)radiotherapy were included. Mean waiting time was 8.5 (±4.2) weeks to surgery and 7.7 (±2.9) weeks to (chemo)radiotherapy. Adjusted for confounders, waiting time to surgery was not significantly associated with OS (continuous HR 0.97 [95%CI: 0.93-1.01], dichotomized HR 0.93 [95%CI: 0.68-1.27], polynomial HR not significant). Similarly, a longer waiting time to (chemo)radiotherapy was not significantly associated with poorer OS (continuous HR 0.97 [95%CI: 0.93-1.00], dichotomized HR 0.91 [95%CI: 0.75-1.09], polynomial HR not significant). CONCLUSIONS: This large population-based study demonstrates that a longer waiting time (of up to 12 weeks) from diagnosis to treatment in patients with cervical cancer treated with curatively intended surgery or (chemo)radiotherapy does not negatively impact survival.
引用
- Hack AP, Zweemer RP, Jonges TN, et al. Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study. Gynecol Oncol. 2022. PMID: 35300853. doi:10.1016/j.ygyno.2022.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。